Ana Benzaquén

Ana Benzaquén

Auto-generated profile, based on publicly available information

Ana Benzaquén

Hematology Department Hospital Clínico Universitario de Valencia‐INCLIVA Valencia Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GIGloria Iacoboni
Gloria Iacoboni
VGVictor Navarro Garcés
Victor Navarro Garcés
AMAna África Martín-López
Ana África Martín-López
KRKai Rejeski
Kai Rejeski
MKmi kwon
mi kwon
PBPere Barba
Pere Barba
PURPOSE: Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS: The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS: The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, of whom 80 had received bendamustine before apheresis. Exposed patients had significantly lower CD3+ cells and platelets at apheresis. These patients had a lower overall response rate (ORR, 53% v 72%; P < .01), a shorter progression-free survival (PFS, 3.1 v 6.2 months; P = .04), and overall survival (OS, 10.3 v 23.5 months; P = .01) in comparison with the bendamustine-naïve group. Following adjustment methods for baseline variables, these differences were mitigated. Focusing on the impact of bendamustine washout before apheresis, those with recent (<9 months) exposure (N = 42) displayed a lower ORR (40% v 72%; P < .01), shorter PFS (1.3 v 6.2 months; P < .01), and OS (4.6 v 23.5 months; P < .01) in comparison with bendamustine-naïve patients. These differences remained significant after IPTW and PSM analysis. Conversely, the cumulative dose of bendamustine before apheresis did not affect CAR-T efficacy outcomes. CONCLUSION: Recent bendamustine exposure before apheresis was associated with negative treatment outcomes after CD19-targeted CAR T-cell therapy and should be therefore avoided in CAR T-cell candidates.

30 April 2024 in Clinical Neurophysiology
Verified
Journal Article
Open access
RHRafael Hernani
Rafael Hernani
MAMika Aiko
Mika Aiko
RVRuth Victorio
Ruth Victorio
ABAna Benzaquén
Ana Benzaquén
APAriadna Pérez
Ariadna Pérez
CSCarlos Solano
Carlos Solano
Immune effector cell-associated neurotoxicity syndrome (ICANS) is common after chimeric antigen receptor T-cell (CAR-T) therapy. This study aimed to assess the impact of preinfusion electroencephalography (EEG) abnormalities and EEG findings at ICANS onset for predicting ICANS risk and severity in 56 adult patients with refractory lymphoma undergoing CAR-T therapy. EEGs were conducted at the time of lymphodepleting chemotherapy and shortly after onset of ICANS. Twenty-eight (50%) patients developed ICANS at a median time of 6 days after CAR-T infusion. Abnormal preinfusion EEG was identified as a risk factor for severe ICANS (50% vs. 17%, P = 0.036). Following ICANS onset, EEG abnormalities were detected in 89% of patients [encephalopathy (n = 19, 70%) and/or interictal epileptiform discharges (IEDs) (n = 14, 52%)]. Importantly, IEDs seemed to be associated with rapid progression to higher grades of ICANS within 24 h. If confirmed in a large cohort of patients, these findings could establish the basis for modifying current management guidelines, enabling the identification of patients at risk of neurotoxicity, and providing support for preemptive corticosteroid use in patients with both initial grade 1 ICANS and IEDs at neurotoxicity onset, who are at risk of neurological impairment.

11 December 2024 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
VEVirginia Escamilla-Gómez
Virginia Escamilla-Gómez
VGValentín García Gutiérrez
Valentín García Gutiérrez
PAPatricia Alcalde-Mellado
Patricia Alcalde-Mellado
BABeatriz Astibia-Mahillo
Beatriz Astibia-Mahillo
ACAnabelle Chinea-Rodriguez
Anabelle Chinea-Rodriguez
GTGeth- Tc
Geth- Tc

2 November 2023 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
ABAna Benzaquén
Ana Benzaquén
EGEstela Giménez
Estela Giménez
GIGloria Iacoboni
Gloria Iacoboni
MGManuel Guerreiro
Manuel Guerreiro
RHRafael Hernani
Rafael Hernani
CSCarlos Solano
Carlos Solano

2 April 2025 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MPM. Peña
M. Peña
DMD. F. Martinez
D. F. Martinez
APA. Paviglianiti
A. Paviglianiti
ABA. Balaguer
A. Balaguer
JSJ. Sanz
J. Sanz
AMA. Mussetti
A. Mussetti

2 November 2023 in Blood
Verified
Journal Article
Open access
BLBlanca Ferrer Lores
Blanca Ferrer Lores
ASAlicia Serrano
Alicia Serrano
RHRafael Hernani
Rafael Hernani
PSPablo Sopena-Novales
Pablo Sopena-Novales
LLLaura Ventura Lopez
Laura Ventura Lopez
MTMaria José Terol
Maria José Terol
Disclosures. Hernandez Boluda:Pfizer, BMS, Incyte, and Novartis: Membership on an entity's Board of Directors or advisory committees. Guerreiro:Novartis, Kite,